Comparison of the Clinical Efficacy of Salmeterol and Sustained-Release Tulobuterol (Patch) on Inadequately Controlled Asthma Patients on Inhaled Corticosteroids

References

• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: Workshop Report. 2005, Update http://www.ginasthma.com
   Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000; 320(7246)1368–373, [CSA]
   PubMed Web of Science ®Google Scholar
• Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107(5 suppl.)783–789, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ind P W, Dal Negro R, Colman N C, et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003; 97(5)555–562, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fish J E, Israel E, Murray J J, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120: 423–430, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92: 641–648, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Stempel D A, O'Donnell J C, Meyer J W. Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109: 433–439, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fjellbirkeland L, Gulsvik A, Palmer J B. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 1994; 88: 599–607, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adachi M, Ohta K, Sano Y, et al. Comparative study of salmeterol/fluticasone propionate combination versus concurrent sustained-release theophylline plus fluticasone propionate in adult Japanese patients with asthma. Allergol Immunol 2005; 12: 922–936, [CSA]
   Google Scholar
• Burioka N, Miyata M, Endo M, et al. Alteration of the circadian rhythm in peak expiratory flow of nocturnal asthma following nighttime treatment β 2-adrenoreceptor agonist tulobuterol chronotherapy. Chronobiol Int 2005; 22: 383–390, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Guideline for the Treatment and Management of Asthma 2003, ed 2, S Makino, M Furusho, T Miyamoto, M Nishima. Immunity & Allergy Research Group, Ministry of Health, Labour and Welfare, Kyowa Kikaku Inc, Tokyo 2003, JGL1998
   Google Scholar
• Miyamoto T, Takishima T, Makino S, et al. Salmeterol xinafoate(SN408). Clinical Consideration on Pharmaceutical Aerosols (9th Report)—a double-blind comparative study with procaterol tablets in adult bronchial asthma. J Clin Therapeut Med 2002; 18: 411–436, [CSA]
   Google Scholar
• Miyamoto T, Takishima T, Takahashi S, et al. Phase III clinical study of transdermal tulobuterol preparation (hn-078) in bronchial asthma—a double-blind intergroup comparative study using procaterol hydrochloride tablets as the control. J Clin Therapeut Med 1995; 11: 783–807, [CSA]
   Google Scholar
• Komase Y, Saito H, Ikehara M, et al. Comparison of salmeterol inhaler and tulobuterol patch–Using Asthma Health Questionnaire E-34 Japan. Prog Med 2004; 24: 1624–1625, [CSA]
   Google Scholar
• Kobayashi H, Sato A, Shikanai T, et al. Consideration on long-acting inhaled β2 stimulants in bronchial asthma patients. Prog Med 2005; 25: 545–546, [CSA]
   Google Scholar
• Yasuba H. Recent long-acting β2 stimulants. Allergol Immunol 2003; 10: 1193–1200, [CSA]
   Google Scholar
• Kimura T, Taniguchi H, Kondoh Y, et al. Comparison of salmeterol inhaler and tulobuterol patch in bronchial asthma patients—evaluation of respiratory function and health control QOL. Prog Med 2004; 24: 1620–1621, [CSA]
   Google Scholar
• Juniper E F, Guyatt G H, Ferrie P J, et al. Measuring quality of life in asthma. Rev Respir Dis 1993; 147: 832–838, [CSA]
   PubMed Web of Science ®Google Scholar
• Juniper E F, Guyatt G H, Willan A, Griffith L E. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81–87, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Evans D J, Taylor D A, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412–1418, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Price D B, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58: 211–216, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bateman E D, Boushey H A, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836–844, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219–224, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kelsen S G, Church N L, Gillman S A. Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 1999; 36: 703–715, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Murray J J, Church N L, Anderson W H, et al. Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999; 20: 173–80, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Noord J A, Schreurs A J, Mol S J, Mulder P G. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999; 54: 207–212, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Juniper E F, Jenkins C, Price M J, James M H. Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Med 2002; 1: 435–440, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Lockey R F, DuBuske L M, Friedman B, et al. Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes. Chest 1999; 115: 666–673, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Hallett C. Salmeterol 100 microg: an analysis of its tolerability in single- and chronic-dose studies. Ann Allergy Asthma Immunol 2001; 87: 465–473, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Uematsu T, Nakano M, Kosuge K, et al. The pharmacokinetics of the β 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur Clin Pharmacol 1993; 44: 361–364, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Kume H. Clinical use of β 2-adrenergic receptor agonists based on their intrinsic efficacy. Allergol Int 2005; 54: 89–97, [CSA], [CROSSREF]
   Google Scholar
• Palmqvist M, Ibsen T, Mellen A, Lotvall J, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 244–249, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kume H, Oguma T, Takeda N, et al. On β 2 adrenoceptor function after administration of long-acting β 2 stimulants; consideration from both the clinical and basic medical point of view. Prog Med 2004; 24: 2073–2075, [CSA]
   Google Scholar
• Johnson M. Combination therapy for asthma: complementary effects of long-acting β 2-agonists and corticosteroids. Curr Allergy Clin Immunol 2002; 15: 16–20, [CSA]
   Google Scholar
• Nelson H S, Chapman K R, Pyke S D, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112: 29–36, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adachi M, Morikawa A, Ishihara K. Asthma insights and reality in Japan (AIRJ). Arerugi 2002; 51: 411–420, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar